Compounds > fenofibric acid
Page last updated: 2024-08-24

fenofibric acid and fluorobenzenes

fenofibric acid has been researched along with fluorobenzenes in 17 studies

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (35.29)29.6817
2010's11 (64.71)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dane, AL; Martin, PD; Schneck, DW; Warwick, MJ1
Kallem, RR; Mullangi, R; Srinivas, NR; Trivedi, RK1
Bays, HE; Buttler, SM; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC1
Filippatos, T; Milionis, HJ1
Awni, WM; Chira, TO; Hosmane, B; Kelly, MT; Pradhan, RS; Sleep, DJ; Stolzenbach, JC; Wan, K; Zhu, T1
Buttler, SM; Davidson, MH; Jones, PH; Kashyap, ML; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC1
Kelly, MT; Kipnes, MS; Lele, A; Rhyne, JM; Roth, EM; Setze, CM; Sleep, DJ; Stolzenbach, JC1
Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K1
Carlson, DM; Gold, A; Jones, PH; Kelly, MT; McKenney, JM; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA1
Blasetto, JW; Carlson, DM; Fukumoto, SM; Khurmi, NS; Rosenson, RS; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA1
Carlson, DM; Gold, A; Jacobson, TA; Kelly, MT; Pepine, CJ; Setze, CM; Stolzenbach, JC; Williams, LA1
Carlson, DM; Hirshberg, B; Kelly, MT; Rosenson, RS; Setze, CM; Stolzenbach, JC; Williams, LA1
Ballantyne, CM; Jones, PH; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Thakker, KM1
Davidson, MH; Ferdinand, KC; Kelly, MT; Setze, CM1
Filippatos, TD1
Ballantyne, CM; Belmont, JW; Brautbar, A; Keinan, A; Ma, L1
Burns, KM; Carlson, DM; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Weinstein, DL; Williams, LA1

Reviews

2 review(s) available for fenofibric acid and fluorobenzenes

ArticleYear
Treatment of hyperlipidaemia with fenofibrate and related fibrates.
    Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10

    Topics: Angiography; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2008
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.
    Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:3

    Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2012

Trials

13 trial(s) available for fenofibric acid and fluorobenzenes

ArticleYear
An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
    Clinical therapeutics, 2003, Volume: 25, Issue:2

    Topics: Adult; Area Under Curve; Cross-Over Studies; Drug Interactions; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors

2003
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
    Clinical drug investigation, 2008, Volume: 28, Issue:10

    Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Prospective Studies; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome

2008
ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans.
    Journal of clinical pharmacology, 2009, Volume: 49, Issue:1

    Topics: Adult; Cross-Over Studies; Drug Interactions; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Young Adult

2009
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
    Atherosclerosis, 2009, Volume: 204, Issue:1

    Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Puerto Rico; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides; United States

2009
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
    Clinical drug investigation, 2010, Volume: 30, Issue:1

    Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2010
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010, Volume: 10, Issue:3

    Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Humans; Hypercholesterolemia; Hypertriglyceridemia; Liver; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2010
Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
    Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:5-6

    Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2010
Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies.
    Clinical cardiology, 2010, Volume: 33, Issue:10

    Topics: Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2010
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
    Cardiovascular drugs and therapy, 2011, Volume: 25, Issue:1

    Topics: Anticholesteremic Agents; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides

2011
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
    Cardiovascular drugs and therapy, 2011, Volume: 25, Issue:1

    Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides

2011
One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Apr-01, Volume: 12, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2012
Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.
    Journal of lipid research, 2012, Volume: 53, Issue:11

    Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Angiopoietins; Apolipoproteins; Apolipoproteins B; Atorvastatin; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2012
A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
    Clinical therapeutics, 2013, Volume: 35, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides; Triglycerides; Young Adult

2013

Other Studies

2 other study(ies) available for fenofibric acid and fluorobenzenes

ArticleYear
Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a clinical study.
    Journal of pharmaceutical and biomedical analysis, 2005, Sep-15, Volume: 39, Issue:3-4

    Topics: Acetates; Calibration; Carbamazepine; Chromatography; Chromatography, Ion Exchange; Chromatography, Liquid; Fenofibrate; Fluorobenzenes; Freezing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Ions; Male; Mass Spectrometry; Models, Chemical; Pyrimidines; Quality Control; Reproducibility of Results; Rosuvastatin Calcium; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Temperature; Time Factors

2005
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010, Volume: 10, Issue:2

    Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2010